The Adipose Mesenchymal Stem Cell Secretome Inhibits Inflammatory Responses of Microglia: Evidence for an Involvement of Sphingosine-1-Phosphate Signalling

Stem Cells and Development

Volumn 25, Issue 14, 2016, Pages 1095-1107

  Marfia, Giovanni ^a   Navone, Stefania Elena ^a   Hadi, Loubna Abdel ^a   Paroni, Moira ^b   Berno, Valeria ^b   Beretta, Matteo ^a   Gualtierotti, Roberta ^c   Ingegnoli, Francesca ^c   Levi, Vincenzo ^a   Miozzo, Monica ^a   Geginat, Jens ^b   Fassina, Lorenzo ^d   Rampini, Paolo ^a   Tremolada, Carlo ^e   Riboni, Laura ^a   Campanella, Rolando ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Istituto Nazionale di Genetica Molecolare   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e Istituto Image   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; FINGOLIMOD; LIPOPOLYSACCHARIDE; SPHINGOSINE 1 PHOSPHATE; CONDITIONED MEDIUM; CYTOKINE; LYSOPHOSPHOLIPID; PROTEOME; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ADIPOSE DERIVED STEM CELL; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEDICAL DEVICE; MESENCHYMAL STEM CELL; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; CELL SEPARATION; CHEMOTAXIS; CONDITIONED MEDIUM; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; INFLAMMATION; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PHARMACOLOGY; PHENOTYPE; SECRETION (PROCESS);

ADIPOSE TISSUE; ADULT; CELL PROLIFERATION; CELL SEPARATION; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; CYTOKINES; DOWN-REGULATION; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LYSOPHOSPHOLIPIDS; MALE; MESENCHYMAL STROMAL CELLS; MICROGLIA; MIDDLE AGED; PHENOTYPE; PROTEOME; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84978397825     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2015.0268     Document Type: Article

References (68)

1. Ransohoff RM and VH Perry. (2009). Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119-145.
2. Streit WJ, SD Hurley, TS McGraw and SL Semple-Rowland. (2000). Comparative evaluation of cytokine profiles and reactive gliosis supports a critical role for interleukin-6 in neuron-glia signaling during regeneration J Neurosci Res 61:10-20.
3. Sawada M, A Suzumura, H Yamamoto and T Marunouchi. (1990). Activation and proliferation of the isolated microglia by colony stimulating factor-1 and possible involvement of protein kinase C. Brain Res 509:119-124.
4. Nimmerjahn A, F Kirchhoff and F Helmchen. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318.
5. Frank-Cannon TC, LT Alto, FE McAlpine and MG Tansey. (2009). Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47-53.
6. Hla T. (2004). Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 5:513-520.
7. Soliven B, V Miron and J Chun. (2011). The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology 76:S9-S14.
8. Kitatani K, K Iwabuchi, A Snider and L Riboni. (2016). Sphingolipids in inflammation: from bench to bedside. Mediators Inflamm 2016:7602526.
9. + channels. Neuroscience 109:827-835.
10. Tham CS, FF Lin, TS Rao, N Yu and M Webb. (2003). Microglial activation state and lysophospholipid acid receptor expression. Int J Dev Neurosci 21:431-443.
11. Nayak D, Y Huo, WX Kwang, PN Pushparaj, SD Kumar, EA Ling and ST Dheen. (2010). Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience 166:132-144.
12. Wei Y, M Yemisci, HH Kim, LM Yung, HK Shin, SK Hwang, S Guo, T Qin, N Alsharif, et al. (2011). Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 69:119-129.
13. Giri RK, SK Selvaraj and VK Kalra. (2003). Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol 170:5281-5194.
14. Lin H, N Baby, J Lu, C Kaur, C Zhang, J Xu, EA Ling and ST Dheen. (2011). Expression of sphingosine kinase 1 in amoeboid microglial cells in the corpus callosum of postnatal rats. J Neuroinflammation 8:13-36.
15. Kimura A, T Ohmori, R Ohkawa, S Madoiwa, J Mimuro, T Murakami, E Kobayashi, Y Hoshino, Y Yatomi and Y Sakata. (2007). Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25:115-124.
16. Choi JW, SE Gardell, DR Herr, R Rivera, CW Lee, K Noguchi, ST Teo, YC Yung, M Lu, G Kennedy and J Chun. (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108:751-756.
17. + monocytes in early lesions of rat traumatic brain injury. J Cell Mol Med 11:307-314.
18. Czech B, W Pfeilschifter, N Mazaheri-Omrani, MA Strobel, T Kahles, T Neumann-Haefelin, A Rami, A Huwiler and J Pfeilschifter. (2009). The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun 389:251-256.
19. Anthony DC, NR Sibson, D Leppert and D Piani Meier. (2010). Fingolimod (FTY720) therapy reduces demyelination and microglial activation in a focal DTH model of multiple sclerosis during the remission phase. Mult Scler 16:S283.
20. Jackson SJ, G Giovannoni and D Baker. (2011). Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation 8:76.
21. Zuk PA, M Zhu, P Ashjian, DA De Ugarte, JI Huang, H Mizuno, XC Alfonso, JK Fraser, P Benhaim and MH Hedrick. (2002). Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:4279-4295.
22. Qin JB, KA Li, XX Li, QS Xie, JY Lin, KC Ye, ME Jiang, GX Zhang and XW Lu. (2012). Long-term MRI tracking of dual-labeled adipose-derived stem cells homing into mouse carotid artery injury. Int J Nanomedicine 7:5191-5120.
23. Marfia G, R Campanella, SE Navone, I Zucca, A Scotti, M Figini, C Di Vito, G Alessandri, L Riboni and E Parati. (2014). Potential use of human adipose mesenchymal stromal cells for intervertebral disc regeneration: a preliminary study on biglycan-deficient murine model of chronic disc degeneration. Arthritis Res Ther 16:457-462.
24. McIntosh KR, T Frazier, BG Rowan and JM Gimble. (2013). Evolution and future prospects of adipose-derived immunomodulatory cell therapeutics. Expert Rev Clin Immunol 9:175-184.
25. Franquesa M, FK Mensah, R Huizinga, T Strini, L Boon, E Lombardo, O DelaRosa, JD Laman, JM Grinyó, et al. (2015). Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 33: 880-891.
26. Kapur SK and AJ Katz. (2013). Review of the adipose derived stem cell secretome. Biochimie 95:2222-2228.
27. Wei X, Z Du, L Zhao, D Feng, G Wei, Y He, J Tan, WH Lee, H Hampel, et al. (2009). IFATS collection: the conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells 27:478-488.
28. Buehrer BM and B Cheatham. (2013). Isolation and characterization of human adipose-derived stem cells for use in tissue engineering. Methods Mol Biol 1001:1-11.
29. Montelatici E, B Baluce, E Ragni, C Lavazza, V Parazzi, R Mazzola, G Cantarella, M Brambilla, R Giordano and L Lazzari. (2015). Defining the identity of human adipose derived mesenchymal stem cells. Biochem Cell Biol 93:74-82.
30. Yoshimura K, T Shigeura, D Matsumoto, T Sato, Y Takaki, E Aiba-Kojima, K Sato, K Inoue, T Nagase, I Koshima and K Gonda. (2006). Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol 208:64-76.
31. Dossena M, G Bedini, P Rusmini, E Giorgetti, A Canazza, V Tosetti, E Salsano, A Sagnelli, C Mariotti, et al. (2014). Human adipose-derived mesenchymal stem cells as a new model of spinal and bulbar muscular atrophy. PLoS One 9:e112746.
32. Shah FS, X Wu, M Dietrich, J Rood and JM Gimble. (2013). A non-enzymatic method for isolating human adipose tissuederived stromal stem cells. Cytotherapy 15:979-985.
33. Bianchi F, M Maioli, E Leonardi, E Olivi, G Pasquinelli, S Valente, AJ Mendez, C Ricordi, M Raffaini, C Tremolada and C Ventura. (2013). A new nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates. Cell Transplant 22:2063-2077.
34. Tremolada C, F Bianchi, C Ventura, C Di Vito, R Campanella, SE Navone, L Riboni, G Marfia and AI Caplan. (2015). Adipose mesenchymal stem cells and "regenerative adipose tissue graft" (lipogems) for musculoskeletal regeneration. Eur J Musc Dis 3:2-8.
35. Giori A, C Tremolada, R Vailati, SE Navone, G Marfia and AI Caplan. (2015). Recovery of function in anal incontinence after micro-fragmented fat graft (Lipogems®) injection: two years follow up of the first 5 cases. CellR4 3:e1544.
36. Gutiérrez-Fernández M, L Otero-Ortega, J Ramos-Cejudo, B Rodríguez-Frutos, B Fuentes and E Díez-Tejedor. (2015). Adipose tissue-derived mesenchymal stem cells as a strategy to improve recovery after stroke. Expert Opin Biol Ther 15:873-881.
37. Chan TM, HJ Harn, HP Lin, SC Chiu, PC Lin, HI Wang, LI Ho, CP Chuu, TW Chiou, et al. (2014). The use of ADSCs as a treatment for chronic stroke. Cell Transplant 23:541-547.
38. Tajiri N, SA Acosta, M Shahaduzzaman, H Ishikawa, K Shinozuka, M Pabon, D Hernandez-Ontiveros, DW Kim, C Metcalf, et al. (2014). Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats. J Neurosci 34:313-326.
39. Kolar MK, PJ Kingham, LN Novikova, M Wiberg and LN Novikov. (2014). The therapeutic effects of human adiposederived stem cells in a rat cervical spinal cord injury model. Stem Cells Dev 23:1659-1674.
40. Masgutov RF, GA Masgutova, MN Zhuravleva, II Salafutdinov, RT Mukhametshina, YO Mukhamedshina, LM Lima, HJ Reis, AP Kiyasov, A Palotás and AA Rizvanov. (2015). Human adipose-derived stem cells stimulate neuroregeneration. Clin Exp Med 6:1-11.
41. Ooi YY, ST Dheen and SS Tay. (2015). Paracrine effects of mesenchymal stem cells-conditioned medium on microglial cytokines expression and nitric oxide production. Neuroimmunomodulation 22:233-242.
42. Yeh DC, TM Chan, HJ Harn, TW Chiou, HS Chen, ZS Lin and SZ Lin. (2015). Adipose tissue-derived stem cells in neural regenerative medicine. Cell Transplant 24:487-492.
43. Carelli S, F Messaggio, A Canazza, DM Hebda, F Caremoli, E Latorre, MG Grimoldi, M Colli, G Bulfamante, et al. (2015). Characteristics and properties of mesenchymal stem cells derived from micro-fragmented adipose tissue. Cell Transplant 24:1233-1252.
44. Navone SE, L Pascucci, M Dossena, A Ferri, G Invernici, F Acerbi, S Cristini, G Bedini, V Tosetti, et al. (2014). Decellularized silk fibroin scaffold primed with adipose mesenchymal stromal cells improves wound healing in diabetic mice. Stem Cell Res Ther 14:1-7.
45. Marfia G, SE Navone, C Di Vito, S Tabano, L Giammattei, A Di Cristofori, R Gualtierotti, C Tremolada, M Zavanone, et al. (2015). Gene expression profile analysis of human mesenchymal stem cells from herniated and degenerated intervertebral discs reveals different expression of osteopontin. Stem Cells Dev 24:320-328.
46. Riboni L, P Viani, R Bassi, P Giussani and G Tettamanti. (2001). Basic fibroblast growth factor-induced proliferation of primary astrocytes: evidence for the involvement of sphingomyelin biosynthesis. J Biol Chem 276:12797-12804.
47. Riboni L, P Viani and G Tettamanti. (2000). Estimating sphingolipid metabolism and trafficking in cultured cells using radiolabeled compounds. Methods Enzymol 311:656-682.
48. Marfia G, R Campanella, SE Navone, C Di Vito, E Riccitelli, LA Hadi, A Bornati, G de Rezende, P Giussani, et al. (2014). Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells. Glia 62:1968-1981.
49. Anelli V, R Bassi, G Tettamanti, P Viani and L Riboni. (2005). Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes. J Neurochem 92:1204-1215.
50. Brinkmann V, A Billich, T Baumruker, P Heining, R Schmouder, G Francis, S Aradhye and P Burtin. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883-897.
51. Mehling M, TA Johnson, J Antel, L Kappos and A Bar-Or. (2011). Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76:S20-S27.
52. Safford KM and HE Rice. (2005). Stem cell therapy for neurologic disorders: therapeutic potential of adiposederived stem cells. Curr Drug Targets 6:57-62.
53. Riazi AM, SY Kwon and WL Stanford. (2009). Stem cell sources for regenerative medicine. Methods Mol Biol 482: 55-90.
54. Fain JN. (2006). Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74:443-477.
55. Yan K, R Zhang, C Sun, L Chen, P Li, Y Liu, L Peng, H Sun, K Qin, et al. (2013). Bone marrow-derived mesenchymal stem cells maintain the resting phenotype of microglia and inhibit microglial activation. PLoS One 8:e84116.
56. Konsman JP, B Drukarch and AM Van Dam. (2007). (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin Sci (Lond) 112:1-25.
57. Gonzalez-Scarano F and G Baltuch. (1999). Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22:219-240.
58. Morganti-Kossmann MC, M Rancan, PF Stahel and T Kossmann. (2002). Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care 2:101-105.
59. McGeer EG and PL McGeer. (2007). The role of antiinflammatory agents in Parkinson's disease. CNS Drugs 21:789-797.
60. Hanisch UK. (2002). Microglia as a source and target of cytokines. Glia 40:140-155.
61. Jiang L, T Womble, S Saporta, N Chen, CD Sanberg, PR Sanberg and AE Willing. (2010). Human umbilical cord blood cells decrease microglial survival in vitro. Stem Cells Dev 19:221-228.
62. Giunti D, B Parodi, C Usai, L Vergani, S Casazza, S Bruzzone, G Mancardi and A Uccelli. (2012). Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1. Stem Cells 30:2044-2053.
63. Jose S, SW Tan, YY Ooi, R Ramasamy and S Vidyadaran. (2014). Mesenchymal stem cells exert anti-proliferative effect on lipopolysaccharide-stimulated BV2 microglia by reducing tumour necrosis factor-α levels. J Neuroinflammation 11:149-161.
64. Liu Y, R Zhang, K Yan, F Chen, W Huang, B Lv, C Sun, L Xu, F Li and X Jiang. (2014). Mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory responses of BV2 microglial cells through TSG-6. J Neuroinflammation 11:135-146.
65. Elahi KC, G Klein, M Avci-Adali, KD Sievert, S MacNeil and WK Aicher. (2016). Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. Stem Cells Int 2016:5646384.
66. Neubrand VE, M Pedreño, M Caro, I Forte-Lago, M Delgado and E Gonzalez-Rey. (2014). Mesenchymal stem cells induce the ramification of microglia via the small RhoGTPases Cdc42 and Rac1. Glia 62:1932-1942.
67. Aoki M, H Aoki, R Ramanathan, NC Hait and K Takabe. (2016). Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm 2016:8606878.
68. Zhi L, BP Leung and AJ Melendez. (2006). Sphingosine kinase 1 regulates pro-inflammatory responses triggered by TNFα in primary human monocytes. J Cell Physiol 208:109-115.